Table 5:
Primary CRT (Cytotoxic or Cetuximab) for FA-HNSCC Primaries
| Patient | Age | Sex | FA Group | SCT (Age) | Tumor site (subsite) | Stage | Systemic Agents (Dose) | RT Dose | Toxicities | Interruption or Termination of CRT | Outcome | Recurrence | Second Primary |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anak #3 (2020)106 | 16 | M | NA | Yes | Oral cavity (retromolar trigone) | T3N3M0 | Cisplatin (30–40 mg/m^2) every 21 days, 5FU (1 g/m^2/per cycle) | 34 Gy total (in 20 fractions) | Mucositis, stomatitis, neutropenia, thrombocytopenia, dysphagia, cerebral edema | Yes (CT and RT terminated) | DOD (6 mo pD) | - | - |
| Spanier 201247 | 27 | M | NA | No | Pharynx (palatine tonsil with extensive infiltration), HPV− | T4N2bM0 | Cisplatin (40 mg/m^2) x1 cycle | 1.4 Gy x4 fractions, 1.8 Gy x4 fractions, reduction to 1.4 Gy fractions (total dose NA) | Pancytopenia (grade 4), diarrhea (grade 1), laryngeal edema, dyspnea, oral candidiasis, emphysema of upper body, bilateral jugular vein thrombosis | Yes (CT and RT terminated) | DOD (NA) | - | - |
| Beehuat Tan 201146 | 32 | F | A | No | Pharynx (pyriform sinus) | T2N2b | Cisplatin (100 mg/m^2) - single dose | Dose NA | Bone marrow failure, neutropenic sepsis, alveolar hemorrhage | Yes (CT and RT terminated) | DOD (NA) | - | - |
| Tipples 2008122 | 25 | F | NA | Yes (10) | Esophagus (upper third) | T3N0 | 5-FU (“25% of normal dose”) | 52.2 Gy total (fractions of 120 cGy increased to 180 cGy) | Dermatitis with desquamation (grade 2), dysphagia | No | DOD (12 mo pD) | Yes | - |
| Salum 2006123 | 16 | M | NA | Yes (5) | Oral cavity (dorsum of tongue) | T3N0M0 | Drug and dose NA (palliative) | Dose NA (palliative) | NA | NA | DOD (4 mo pCRT) | Yes | - |
| Bremer #1 (2003)49 | 24 | M | A | No | Pharynx (BOT) | T4cN2G2M0 | Carboplatin (60 mg/m^2) x1 cycle | 67 Gy total [break at 38.4 Gy], fractions of 160–180 cGy | Mucositis (confluent) after 2720 cGy, pancytopenia (grade 3) | Yes (RT interrupted, CT terminated) | Died of SP after 5 yr (see below) | - | Oral cavity* [Table 5], anal |
| Bremer #1 (2003)49 | 29 | M | A | No | Oral cavity (floor of mouth) | NA | Gemcitabine (100 mg/m^2) once weekly x3 weeks | 25.2 Gy total (fractions of 180 cGy) | Mucositis (grade 2), thrombocytopenia, anemia | No | DOD (3 mo pCRT) | - | - |
| Bradford 199075 | 29 | F | NA | Yes (20) | Pharynx (tonsillar fossa and BOT) | T4N0M0 | Cisplatin (100 mg/m^2) and 5-FU (500 mg/m^2) x2 cycles | 72.2 Gy total [3 breaks] | Mucositis, stomatitis, conjunctivitis, pneumonia | Yes (RT interrupted, CT terminated) | DOD (6 mo pRT) | Yes | - |
| Kutler #26 (2016)4 | 24.2 | M | A | No | Oral cavity (tongue) | NA | Cetuximab (dose NA) | Dose NA | NA | No | DOD (NA) | - | - |